OBJECTIVE: To describe the presentation, resolution of symptoms, processes of care, and outcomes of pneumococcal pneumonia, and to compare features of the bacteremic and nonbacteremic forms of this illness.
DESIGN: A prospective cohort study.
SETTING: Five medical institutions in 3 geographic locations.
PARTICIPANTS: Inpatients and outpatients with communityacquired pneumonia (CAP).
MEASUREMENTS: Sociodemographic characteristics, respiratory and nonrespiratory symptoms, and physical examination findings were obtained from interviews or chart review. Severity of illness was assessed using a validated prediction rule for short-term mortality in CAP. Pneumococcal pneumonia was categorized as bacteremic; nonbacteremic, pure etiology; or nonbacteremic, mixed etiology.
MAIN RESULTS: One hundred fifty-eight (6.9%) of 2,287 patients (944 outpatients, 1,343 inpatients) with CAP had pneumococcal pneumonia. Sixty-five (41%) of the 158 with pneumococcal pneumonia were bacteremic; 74 (47%) were nonbacteremic with S. pneumoniae as sole pathogen; and 19 (12%) were nonbacteremic with S. pneumoniae as one of multiple pathogens. The pneumococcal bacteremia rate for outpatients was 2.6% and for inpatients it was 6.6%. Cough, dyspnea, and pleuritic pain were common respiratory symptoms. Hemopytsis occurred in 16% to 22% of the patients. A large number of nonrespiratory symptoms were noted. Bacteremic patients were less likely than nonbacteremic patients to have sputum production and myalgias (60% vs 82% and 33% vs 57%, respectively; P<.01 for both), more likely to have elevated blood urea nitrogen and serum creatinine levels, and more likely to receive pencillin therapy. Half of bacteremic patients were in the low risk category for short-term mortality (groups I to III), similar to the nonbacteremic patients. None of the 32 bacteremic patients in risk groups I to III died, while 7 of 23 (30%) in risk group V died. Intensive care unit admissions and pneumonia-related mortality were similar between bacteremic and nonbacteremic groups, although 46% of the bacteremic group had respiratory failure compared with 32% and 37% for the other groups. The nonbacteremic pure etiology patients returned to household activities faster than bacteremic patients. Symptoms frequently persisted at 30 days: cough (50%); dyspnea (53%); sputum production (48%); pleuritic pain (13%); and fatigue (63%).
CONCLUSIONS: There were few differences in the presentation of bacteremic and nonbacteremic pneumococcal pneumonia. About half of bacteremic pneumococcal pneumonia patients were at low risk for mortality. Symptom resolution frequently was slow.
Mundy LM, Auwaerter PG, Oldach D, et al. Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med. 1995;152:1309–15.PubMedGoogle Scholar
Fang G-D, Fine M, Orloff J, Arisumi D, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicentre study of 359 cases. Medicine. 1990;69:307–16.PubMedCrossRefGoogle Scholar
Ortqvist A, Kalin M, Julander J, Mufson MA. Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations—Huntington, WVa and Stockholm, Sweden. Chest. 1993;103:710–6.PubMedGoogle Scholar
Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Arch Intern Med. 1964;60:759–66.Google Scholar
Kramer MR, Rudensky B, Hadas-Halperin IN, et al. Pneumococcal bacteremia: no change in mortality over 30 years—analysis of 104 cases and review of the literature. Isr J Med Sci. 1987;23:174–80.PubMedGoogle Scholar
Hook EW III, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal pneumonia. JAMA. 1983;249:1055–7.PubMedCrossRefGoogle Scholar
Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drugresistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995;333:481–6.PubMedCrossRefGoogle Scholar
Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333:474–80.PubMedCrossRefGoogle Scholar
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50.PubMedCrossRefGoogle Scholar
Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia. Results from the pneumonia patient outcomes research team. Arch Intern Med. 1999;159:970–80.PubMedCrossRefGoogle Scholar
Manual of the international statistical classification of diseases, injuries, and causes of death. Geneva, Switzerland: World Health Organization; 1977.Google Scholar
Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of communityacquired pneumonia requiring hospitalization. Results of a population based active surveillance study in Ohio. Arch Intern Med. 1997;157:1709–18.PubMedCrossRefGoogle Scholar
Burman LA, Trollfors B, Andersson B, et al. Diagnosis of pneumonia by cultures, bacterial and viral antigen detection tests, and serology with special influence to antibodies against pneumococcal antigens. J Infect Dis. 1991;163:1087–93.PubMedGoogle Scholar
Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis. 1995;172:1330–5.PubMedGoogle Scholar
Fay HM, Wentworth B, Kenny GE, Kloeck JM, Grayston JT. Pneumococcal isolation from patients with pneumonia and control subjects in a prepaid medical care group. Am Rev Respir Dis. 1975;111:595–603.Google Scholar
Bates JH, Campbell GD, Barren AC, et al. Microbiology etiology of acute pneumonia in hospitalized patients. Chest. 1992;101:1005–112.PubMedGoogle Scholar
Gilbert K, Gleason PP, Singer DE, et al. Variation in antimicrobial use and cost in more than 2000 patients with community-acquired pneumonia. Am J Med. 1998;104:17–27.PubMedCrossRefGoogle Scholar
Goldstein EJC. CID Hot Page. Clinic Infect Dis. 1997;24.Google Scholar
Butler JC, Hofmann J, Cetron MS, et al. The continuing emergence of drug-resistant Streptococcus pneumoniae in the United States. An update from Centers for Disease Control and Prevention’s pneumococcal sentinel surveillance system. J Infect Dis. 1996;174:986–93.PubMedGoogle Scholar
British Thoracic Society Research Committee. The aetiology management and outcome of severe community-acquired pneumonia in the intensive care unit. Respir Med. 1992;86:7–13.CrossRefGoogle Scholar
Rello J, Quintana E, Ausina V, Net A, Prats G. A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest. 1993;103:232–5.PubMedGoogle Scholar
Finkelstein MS, Petkun WM, Freedman ML, Antopol SC. Pneumococcal bacteremia in adults. Age-dependent differences in presentation and outcome. J Am Geriatr Soc. 1983;31:19–27.PubMedGoogle Scholar
Ortqvist A, Grepe A, Julander IN, Kalin M. Bacteremic pneumococcal pneumonia in Sweden: Clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias. Scand J Infect Dis. 1988;20:163–71.PubMedGoogle Scholar
Tilghman RC, Finland M. Clinical significance of bacteremia in pneumococcic pneumonia. Arch Intern Med. 1937;59:602–19.Google Scholar
Perlino CA, Rimland D. Alcoholism, leukopenia and pneumococcal sepsis. Am Rev Respir Dis. 1985;132:757–60.PubMedGoogle Scholar
Kludt P, Lett SM, De Maria, et al. Outbreaks of pneumococcal pneumonia among unvaccinated residents in chronic care facilities—Massachusetts, October 1995, Oklahoma, February 1996 and Maryland, May–June 1996. MMWR. 1997;46:60.Google Scholar
Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med. 1997;12:423–30.PubMedCrossRefGoogle Scholar
Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors incommunity-acquired bacteremic pneumococcal disease in five countries. Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif. 1999;675. Abstract 1068.Google Scholar